Skip to content
You can now search across every topic, entity and event.What's new
Pandemics and Biosecurity
16JUN

Uganda Ebola cases jump from 2 to 9

3 min read
10:26UTC

Uganda's confirmed Bundibugyo cases rose from 2 to 9 in DON605, all in Kampala and neighbouring Wakiso. A country this good at case-finding moving in that direction signals onward transmission, not a single traveller.

ScienceDeveloping
Key takeaway

Uganda's confirmed cases rose from 2 to 9 in Kampala and Wakiso, signalling genuine onward transmission across the border.

Uganda's confirmed Bundibugyo Ebola cases rose from 2 to 9 in WHO bulletin DON605 on 29 May, all in the capital Kampala and the neighbouring district of Wakiso 1. The Kampala index case had been imported from DRC three weeks earlier ; nine cases now means onward transmission inside Uganda, not a single returning traveller.

That movement matters more than the raw DRC totals. Uganda has strong surveillance and a track record: in 2022 it contained a Sudan ebolavirus outbreak of 142 confirmed cases in 113 days without any licensed vaccine. A health system that effective at case-finding does not move from 2 to 9 as a testing artefact.

WHO Director-General Tedros Adhanom Ghebreyesus said on Monday 25 May that the outbreak was "outpacing us" 2. The cross-border spread forces a second national response axis, splitting scarce trained-responder capacity across two countries at once. Uganda contained its last Ebola outbreak with a functioning state health authority able to compel and protect contacts; whether it holds these nine cases as tightly is the test now running.

Deep Analysis

In plain English

Uganda is a country that shares a long border with DRC, where the Ebola outbreak is centred. A person who had been in DRC travelled to Kampala, Uganda's capital, and later tested positive for Ebola. That person has now passed the virus to at least eight more people in Kampala and the surrounding Wakiso district. This matters for two reasons. First, Kampala is a city of more than two million people, which makes tracing and isolating everyone who may have been exposed much harder than in a rural area. Second, Uganda had previously managed to stop an Ebola outbreak in 2022 without a vaccine, by rapidly finding and isolating every contact. Health authorities are now trying to do the same thing again, but for a different Ebola strain with no approved treatment at all.

Deep Analysis
Root Causes

Uganda shares an ~877-kilometre land border with DRC, with the most active crossing at Bwera-Kasindi directly adjacent to the outbreak's Ituri epicentre.

Cross-border movement for gold mining, trade, and healthcare-seeking is not captured by formal border surveillance: the WHO PHEIC technical assessment noted on 17 May that the outbreak had been circulating for at least four weeks before detection, meaning DRC-Uganda population movement during that undetected period brought infected individuals to Kampala before any exit screening was in place.

A second structural cause is the absence of a licensed Bundibugyo treatment that Uganda could use for ring prophylaxis or trial dosing. In the 2022 Sudan ebolavirus response, Uganda had access to a candidate vaccine (the Sabin Institute's ChAdOx Sudan candidate, under emergency protocol) and could offer enrolled contacts an intervention beyond surveillance alone. No comparable option exists for Bundibugyo as of 29 May.

What could happen next?
  • Risk

    Kampala's two-million-person population and high referral-hospital utilisation rate create conditions for healthcare-associated amplification if isolation protocols are not applied early to all confirmed contacts.

  • Precedent

    If Uganda contains the Kampala cluster using contact-tracing alone, it will become the first documented example of urban Bundibugyo containment without countermeasures, informing WHO protocols for future non-Zaire Ebola introductions in capital cities.

First Reported In

Update #5 · Ebola money arrives, the cure does not

World Health Organization· 2 Jun 2026
Read original
Different Perspectives
Indian Council of Medical Research
Indian Council of Medical Research
ICMR deployed a team to Kerala within hours of the 11 June Nipah confirmation in Kozhikode, tracing roughly 100 contacts including 58 healthcare workers; three days without fresh positives suggest containment of a pathogen with no licensed vaccine and a case-fatality rate of 40 to 75 percent.
ECDC / European Union
ECDC / European Union
ECDC's Week 23 Communicable Disease Threats Report carried four simultaneous non-Ebola signals including the first peer-reviewed evidence of Dermatophilus congolensis sexual transmission, local mpox clade Ib European spread, and the Dermatophilus rapid risk assessment due 23 June. European import risk for Bundibugyo is assessed as very low.
United States (HHS / State Department)
United States (HHS / State Department)
Washington committed $270 million bilaterally to the response on 12 June while its 30-day entry ban on DRC, Uganda and South Sudan nationals, extended to green-card holders on 5 June, expired around 17 June unresolved. The CDC's R0=2.51 modelling is the sharpest analytical contribution to the response from any national agency.
World Health Organization
World Health Organization
DON607's publication on 13 June provides the 695-case international reference and attributes the treatment trial design to national leadership rather than WHO advisory consensus; the WHO co-authors the Continental Strategic Plan with Africa CDC but holds no enforcement lever over the US entry ban expiring 17 June.
Uganda Ministry of Health
Uganda Ministry of Health
Diana Atwine's ministry traced the 14-imported-case Uganda cluster using protocols rehearsed in the 2022 Sudan ebolavirus containment of 142 cases in 113 days; Uganda co-authorises the treatment trial and Bwera border lab reduces cross-border confirmation to same-day. Nineteen confirmed cases with five from onward Kampala transmission test whether the Sudan playbook transfers.
DRC Ministry of Health
DRC Ministry of Health
Kinshasa's 14 June bulletin counted 782 confirmed cases with 45.9 percent isolated, a figure DRC's health minister has linked directly to ongoing attacks on treatment facilities rather than community resistance. DRC co-leads the clinical trial now under national authority, a regulatory posture that keeps Geneva's timeline advisory, not binding.